Quarterly report pursuant to Section 13 or 15(d)

Segment Information (Tables)

v3.22.2.2
Segment Information (Tables)
9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Schedule of Reconciliation of Revenue from Segments to Consolidated The following table provides a reconciliation of revenue and operating income by reportable segment to consolidated results and was derived from each segment’s internal financial information as used for corporate management purposes (in thousands):
Three Months Ended September 30, Nine Months Ended September 30,
2022 2021 2022 2021
OmniAb business revenue
  Royalties $ 582  $ —  $ 984  $ — 
  Contract 6,285  5,140  22,353  19,520 
Total OmniAb business revenue
6,867  5,140  23,337  19,520 
Ligand core business revenue
  Royalties 19,255  15,648  50,507  $ 31,376 
  Captisol - Core 3,582  5,374  13,133  16,310 
  Captisol - COVID 32,367  29,719  64,483  112,565 
  Contract 4,017  8,954  17,740  24,889 
 Total Ligand core business revenue 59,221  59,695  145,863  185,140 
     Total revenue $ 66,088  $ 64,835  $ 169,200  $ 204,660 
Segment operating income (loss)
OmniAb business
$ (11,721) $ (9,177) $ (26,905) $ (21,587)
Ligand core business 22,022  32,620  49,050  112,601 
Total segment operating income 10,301  23,443  22,145  91,014 
Unallocated corporate items
Shared-based compensation 6,462  5,811  17,255  16,429 
Other corporate expenses 3,203  1,926  14,029  8,424 
  Total unallocated corporate items 9,665  7,737  31,284  24,853 
Income (loss) from operations $ 636  $ 15,706  $ (9,139) $ 66,161